{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:12:15Z","timestamp":1761484335860,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.neo.2020.07.005","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T19:51:43Z","timestamp":1599853903000},"page":"533-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Degrading AR-dependent cancers: Expanding the role of PROTACs"],"prefix":"10.1016","volume":"22","author":[{"given":"Anna R.","family":"Michmerhuizen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Speers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2020.07.005_b0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41585-020-0298-8","article-title":"Cellular rewiring in lethal prostate cancer: the architect of drug resistance","volume":"17","author":"Carceles-Cordon","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.neo.2020.07.005_b0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-017-0038-2","article-title":"Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer","volume":"3","author":"Speers","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.neo.2020.07.005_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00492","article-title":"The androgen receptor in breast cancer","volume":"9","author":"Giovannelli","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.neo.2020.07.005_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccr.2011.05.026","article-title":"Targeting androgen receptor in estrogen receptor-negative breast cancer","volume":"20","author":"Ni","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2020.07.005_b0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/modpathol.2011.54","article-title":"Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses\u2019 Health Study","volume":"24","author":"Collins","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.neo.2020.07.005_b0030","first-page":"1","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.neo.2020.07.005_b0035","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1021\/acs.jmedchem.9b01393","article-title":"Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands","volume":"62","author":"Han","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.neo.2020.07.005_b0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neo.2019.12.003","article-title":"Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment","volume":"22","author":"Kregel","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.neo.2020.07.005_b0045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.neo.2020.07.005_b9005","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-20-0095","article-title":"Expression of the androgen receptor governs radiation resistance in a subset of glioblastomas vulnerable to anti-androgen therapy","author":"Werner","year":"2020","journal-title":"Mol Cancer Ther."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:06:53Z","timestamp":1761484013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558620301366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1476558620301366"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2020.07.005","relation":{},"ISSN":["1476-5586"],"issn-type":[{"type":"print","value":"1476-5586"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Degrading AR-dependent cancers: Expanding the role of PROTACs","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2020.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2020.07.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}